|
⚲
|
| Keyboard |
| Stempoint Capital LP
✚
|
|
|---|---|
| CRD # | 324248 |
| SEC # | 801-127041 |
| CIK # | 0001952142 |
| AUM | 761.3 M (2026-03-30) |
| Employees | 7 (57% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 212-540-4099 |
| Address | 520 Madison Avenue New York, NY 10022 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| In the News | |
|---|---|
| Thu, 30 Jul 2026 | Stempoint Capital LP Takes $1.23 Million Position in LB Pharmaceuticals Inc $LBRX — MarketBeat |
| Thu, 30 Jul 2026 | Stempoint Capital LP Has $34.94 Million Stock Position in Abivax SA Sponsored ADR $ABVX — MarketBeat |
| Thu, 30 Jul 2026 | Stempoint Capital LP Acquires New Holdings in Biodesix, Inc. $BDSX — MarketBeat |
| Thu, 30 Jul 2026 | Stempoint Capital LP Makes New $4.89 Million Investment in Nurix Therapeutics, Inc. $NRIX — MarketBeat |
| Thu, 30 Jul 2026 | Stempoint Capital LP Buys 125,581 Shares of Evommune, Inc. $EVMN — MarketBeat |
| Fees and Compensation — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Item 5: Fees and Compensation
Unless otherwise provided in applicable side letters, StemPoint Capital is compensated
for its advisory services with respect to each Fund as follows:
• StemPoint Fund: StemPoint Capital is entitled to receive a monthly management
fee from the StemPoint Fund, payable in advance. The management fee for a
calendar month equals 1/12 of the applicable management percentage of each
sub-account balance maintained by the StemPoint Fund calculated as of the first
business day of such month. “Applicable management percentage” means 2.0%
(per annum) for Class A interests and their corresponding sub-accounts and 1.5%
(per annum) for Class F interests and their corresponding sub-accounts.
The general partner of the StemPoint Master Fund is eligible to receive a
performance allocation, which is compensation that is based on a share of capital
gains on or capital appreciation of the assets of the StemPoint Fund (if any). This
compensation is 20.0% for Class A interests and 17.5% for Class F interests.
Performance allocation paid is less management fees and subject to a loss
carryforward.
• Opportunity Fund: StemPoint Capital is entitled to receive a quarterly
management fee from the Opportunity Fund, payable in advance. The
management fee for a calendar quarter will equal 1/4 of the management fee for
each sub-account balance maintained by the Opportunity Fund calculated as of
the first business day of such quarter and the management fee will be prorated for
any partial calendar quarter. “Applicable management percentage” means 1.0%
(per annum) for Class A interests and their corresponding sub-accounts.
If the performance allocation for a given year is greater than the management fee
agreed upon with investors in the Opportunity Fund for that year, then the general
partner of the Opportunity Master Fund is eligible to receive a performance
allocation calculated with respect to each Opportunity Fund Class A interest sub-
account that equal 30.0% of the excess (if any) of the capital appreciation of the
assets of such sub-account over a hurdle amount as outlined in the respective
applicable offering documents. The performance allocation with respect to a sub-
account for any performance period will be reduced (but not below zero) by an
amount equal to the sum of the management fees payable by the Opportunity
Fund in respect of such sub-account and any unrecovered Management Fee
Carryforward (defined below) balance that has not been applied to reduce
performance allocations from prior periods. To the extent any portion of the
management fees payable in respect of a sub-account is not applied to reduce any
performance allocation for such performance period (e.g., because the amount of
management fees payable for such period exceeds the amount of the performance
allocation for such period), such portion of the management fees will be carried
forward to reduce any future performance allocations (such excess management
fees carried forward, “Management Fee Carryforward”).
StemPoint Capital’s fees with respect to the Funds are generally not negotiable.
Notwithstanding the foregoing, the Firm offers more favorable fee terms to certain
investors in a separate class in one or more of the Funds, including to the Firm’s
employees, officers, consultants and associated persons or vehicles.
StemPoint Capital has the ability to waive, reduce or calculate differently the
management fee applicable to any investor of the Funds without the consent of, or notice
to, any other investor. The management fee payable in respect of an investor will be
specially allocated by the particular Fund to the sub-account maintained at the respective
Funds with respect to such investor. The general partners of the respective Funds have
the ability to reduce, waive or calculate differently the performance allocation with
respect to any sub-account established from time to time with respect to any investor.
With respect to the Strategic Investor SMA, StemPoint Capital is entitled to receive a
quarterly management fee, payable in advance, calculated at a rate of 1.5% (per annum)
based on the notional value of the managed account as of the first calendar day of each
calendar quarter and is eligible to receive an annual incentive fee equal to 17.5% of the
net profits for each fiscal year.
In connection with the Sub-Advisory Agreement, StemPoint Capital is entitled to receive
a monthly management fee of 0.50% (annualized), payable in advance, of the net asset
value from each series of certain share classes of the Segregated Portfolio. The Firm is
also eligible to receive an annual performance fee of 10% of the aggregate net profits
allocated to each series of certain share classes of the Segregated Portfolio, subject to
certain hurdles and high watermarks as specified in the offering documents of the
Segregated Portfolio.
In addition to the management fee and performance allocation or fee described above,
each Fund shall bear its own expenses. Such expenses vary by Fund, but generally
include, but are not limited to, the following: (A) organizational and offering expenses
of each Fund, including, without limitation, all expenses incurred in connection with and
directly and indirectly related to the formation, qualification, and registration and/or
exemption from qualification and registration of the Funds and their ownership interests
or shares and the offering, distribution, and processing of the ownership interests or
... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Item 7: Types of Clients
StemPoint Capital provides investment advisory services with respect to the Clients, as
described above in Item 4: Advisory Business.
The offering of the Funds is designed to be exempt from registration under the Securities
Act of 1933, as amended (the “Securities Act”) pursuant to Regulation D thereunder. In
addition, each Fund is designed to rely on an exemption from registration as an
investment company under the Investment Company Act pursuant to Section 3(c)(7) of
the Investment Company Act. Each investor in the Funds must meet certain eligibility
provisions.
Admission to the Funds is not open to the general public. Interests in the Funds will
generally be offered and sold only to sophisticated investors that are (i) “accredited
investors” within the meaning of Rule 501 of Regulation D under the Securities Act, (ii)
“qualified clients” as defined in Rule 205-3 under the Investment Advisers Act of 1940,
as amended (the “Advisers Act”), and (iii) either “qualified purchasers” or “knowledgeable
employees” as defined under Section 3(c)(7) and Rule 3c-5 under the Investment Company
Act, respectively.
Investors that invest in one or more of the Funds generally include educational endowments,
high net worth individuals, family offices, trusts, foundations, fund of funds or other
registered investment advisers.
The minimum initial investment amount for the StemPoint Fund is $1 million for Class
A interests and $10 million for Class F interests. Subsequent subscriptions must be at
least $500,000 for Class A interests and $5,000,000 for Class F interests. The minimum
initial investment amount for the Opportunity Fund is $1 million for Class A interests.
Subsequent subscriptions must be at least $500,000 for Class A interests. However, these
amounts can be waived or reduced at the discretion of the general partners and/or board
of directors of each respective Fund. |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Scholar Rock Holding Corp | 111.6 | ||
| Revolution Medicines Inc | 74.2 | ||
| Abivax Sa | 69.9 | ||
| Syndax Pharmaceuticals Inc | 63.8 | ||
| Health Sciences Acquisitions Corp | 42.1 | ||
| Praxis Precision Medicines Inc | 36.3 | ||
| Boston Scientific Corp | 31.4 | ||
| MBX Biosciences Inc | 29.8 | ||
| Mineralys Therapeutics Inc | 28.9 | ||
| Imara Inc | 28.5 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Stempoint Capital Opportunity Master Fund LP | [2025-03-28] | 75.7 M | 137.0 M |
| Filed 2025-10-03 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $500,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Stempoint Capital Master Fund LP | [2023-02-02] | 72.4 M | 447.4 M |
| Filed 2025-10-03 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $250,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 7 | 645.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 116.3 |
| (n) Other | 0 | 0.0 |
| Total | 8 | 761.3 |
| By Discretionary | ||
| Discretionary | 8 | 761.3 |
| Non-Discretionary | 0 | 0.0 |
| Total | 8 | 761.3 |
| By Non-United States Persons | ||
| Non-United States Persons | 645.0 | |
| United States Persons | 116.3 | |
| Total | 8 | 761.3 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Robert Duggan | Director | 29 | 7 | |
| Miles Perryman | Director | 8 | 4 | |
| Sean Tan | Director | 9 | 2 | |
| Stempoint Capital LP | Promoter | 4 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001952142] | |
| SC 13G | [0001952142] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Stempoint Capital LP | Sensei Biotherapeutics Inc | [2026-05-15] |
| Stempoint Capital LP | Xilio Therapeutics Inc | [2025-11-14] |
| Stempoint Capital LP | Surrozen Inc/DE | [2024-11-01] |
| Stempoint Capital LP | Vistagen Therapeutics Inc | [2024-02-12] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300SQHSDQCTFLCL20 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Benchmark Plus Management LLC
✚
|
WA | 767.4 M |
|
Coinfund Management LLC
✚
|
NY | 766.0 M |
|
Orange Investment Advisors LLC
✚
|
FL | 765.0 M |
|
Lepercq de Neuflize Asset Management LLC
✚
|
NY | 763.7 M |
|
Stonecastle Advisors LLC
✚
|
NY | 763.4 M |
|
Sciencast Management LP
✚
|
NJ | 760.0 M |
|
Shrewsbury River Capital LP
✚
|
NJ | 757.5 M |
|
Riva Ridge Capital Management LP
✚
|
NY | 757.5 M |
|
Mill Hill Capital LLC
✚
|
NY | 757.2 M |
|
Alight Capital Management LP
✚
|
NY | 754.4 M |